PhotoCure's Metvix: Creating a New Market
Executive Summary
Norway's PhotoCure is one of the few European biotech companies with a marketed product. Skin cancer photodynamic therapy Metvix PDT has already been launched in Scandinavia, and more recently by partner Galderma in Germany and the UK. Other PDT firms have struggled to educate physicians to accept a new kind of treatment-and thereby recoup the costs attached. PhotoCure is hoping that Metvix's improved efficacy and cosmetic advantages will help it create a market for PDT products.
You may also be interested in...
Photobiotics Ltd.
Imperial College spin-out Photobiotics reckons it's on track towards making photodynamic therapy (PDT) more targeted, as well as addressing some of the technique's other weaknesses.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.